1、Barclays Capital Inc.and/or one of its affiliates does and seeks to do business with companiescovered in its research reports.As a result,investors should be aware that the firm may have aconflict of interest that could affect the objectivity of this report.Investors should consider thisreport as on

2、ly a single factor in making their investment decision.This research report has been prepared in whole or in part by equity research analysts basedoutside the US who are not registered/qualified as research analysts with FINRA.Please see analyst certifications and important disclosures beginning on

3、page 4.RocheLive from Madrid:CT-388 weight losscomes at a costIn todays poster,the rapid weight loss of Roches GLP-1/GIP RACT-388 was confirmed showing no plateauing at week 24;however this comes at a cost of tolerability,with30%rates ofGI side effects continuing to be seen in the maintenance phase.

4、Can this be fixed with less aggressive titration going forward?Were on the ground in Madrid attending the European Association for the Study ofDiabetes(EASD)annual meeting.Though the full dataset for Roches once-weeklysubcutaneous GLP-1/GIP-RA wasnt scheduled to be presented until Thursday(for ourpl

5、anner,see:EASD 2024 Planner(03/09/24),EASD released a poster with efficacy and safetydetails today.The poster confirmed the weight loss profile as disclosed in the earlierabstract and did not show a plateauing of weight loss at 22mg at 24 weeks with weightloss of 18.9%(see:EASD abstract shows no dis

6、continuations for CT-388,keeping the obesitytrade running(15/07/24);well ahead of LLYs tirzepatide,which was in the mid-teens for the10mg and 15mg dosing arms in the SURMOUNT-1 P3 study.That said,this aggressive weightloss came at a cost,with rates of=50%for GIAEs of nausea,constipation and diarrhea